Welcome to our dedicated page for United States Antimony SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United States Antimony Corporation filings document the public-company record for an antimony, zeolite and critical-minerals producer and processor. Recent 8-K reports cover operating and financial results, conference-call materials, officer and finance-leadership changes, and operational updates tied to the Fostung tungsten property and its Technical Report Summary.
The company’s proxy materials describe annual-meeting voting matters and shareholder governance procedures. Its Form 25 records the withdrawal of common stock from NYSE American following the completed transfer of the listing to the New York Stock Exchange, while later current reports identify UAMY common stock as listed on the NYSE and NYSE Texas. The filings also disclose the company’s common stock class, par value, reporting status, and material-event exhibits.
Form 144 filing for UNITED STATES ANTIMONY CORP (UAMY) reports a proposed sale of 50,000 common shares through Merrill Lynch in New York with an aggregate market value of $365,791.80 and an approximate sale date of 10/01/2025. The filer reports acquiring 135,000 of the shares on 08/14/2024 in an open market purchase paid in cash. The issuer has 128,727,843 shares outstanding as stated. The notice includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Gary C. Evans, Chairman & CEO and a director of United States Antimony Corp (UAMY), reported a purchase of 100,000 shares of the company on 09/26/2025 at a price of $6.132 per share. Following the transaction, Mr. Evans beneficially owns 2,378,818 shares. The Form 4 was filed as a single reporting person filing and bears Mr. Evans' signature dated 09/26/2025.
Gary C. Evans, Chairman & CEO of United States Antimony Corp (UAMY), reported grants on 05/27/2025 consisting of 750,000 restricted stock units (RSUs) and a stock option covering 750,000 shares with an exercise price of $2.57. One-third of the RSU award (250,000 shares) vested on 05/27/2025 and the remaining two tranches vest on 05/27/2026 and 05/27/2027, subject to continued service and shareholder approval of the issuer’s Amended and Restated 2023 Equity Incentive Plan. The option award vests only upon meeting specified performance measures anytime during its 10-year term and is also subject to shareholder approval. The Form 4 was signed by Mr. Evans on 09/16/2025.
United States Antimony Corporation disclosed that it has been awarded a $245 million sole-source, five-year contract from the U.S. Defense Logistics Agency to supply antimony ingots. This long-term government contract provides a defined revenue stream tied to antimony deliveries over the contract term. The company announced the award in a press release dated September 23, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
United States Antimony Corporation disclosed that it has been awarded a $245 million sole-source, five-year contract from the U.S. Defense Logistics Agency to supply antimony ingots. This long-term government contract provides a defined revenue stream tied to antimony deliveries over the contract term. The company announced the award in a press release dated September 23, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
United States Antimony Corp (UAMY) insider award disclosure: Director and EVP Lloyd Bardswich was granted time-based restricted stock units totaling 180,000 shares and stock options covering 225,000 shares on 05/27/2025. The RSUs vest one-third on 05/27/2025 and the remainder in equal annual tranches through 05/27/2027, subject to continued service and shareholder approval of the company's Amended Restated 2023 Equity Incentive Plan. The options carry a $2.57 exercise price and vest upon achievement of specified performance measures at any time during their 10-year term, also subject to continued service and shareholder approval. The Form 4 reports these awards as beneficially owned following the transactions and is signed by Lloyd Joseph Bardswich on 09/18/2025.
United States Antimony Corp (UAMY) insider award disclosure: Director and EVP Lloyd Bardswich was granted time-based restricted stock units totaling 180,000 shares and stock options covering 225,000 shares on 05/27/2025. The RSUs vest one-third on 05/27/2025 and the remainder in equal annual tranches through 05/27/2027, subject to continued service and shareholder approval of the company's Amended Restated 2023 Equity Incentive Plan. The options carry a $2.57 exercise price and vest upon achievement of specified performance measures at any time during their 10-year term, also subject to continued service and shareholder approval. The Form 4 reports these awards as beneficially owned following the transactions and is signed by Lloyd Joseph Bardswich on 09/18/2025.
United States Antimony Corporation entered into an Amended and Restated Sales Agreement with A.G.P./Alliance Global Partners and B. Riley Securities to sell common stock through an at-the-market offering program. The agreement adds B. Riley as a sales agent and updates related terms.
The company filed a prospectus supplement to allow issuance of up to $65,000,000 of common shares under this program using its existing shelf registration. The company will set limits on timing, size, and minimum prices for sales, may suspend sales at its discretion, and will pay the sales agents up to 3.0% of gross proceeds as commission.
United States Antimony Corporation entered into an Amended and Restated Sales Agreement with A.G.P./Alliance Global Partners and B. Riley Securities to sell common stock through an at-the-market offering program. The agreement adds B. Riley as a sales agent and updates related terms.
The company filed a prospectus supplement to allow issuance of up to $65,000,000 of common shares under this program using its existing shelf registration. The company will set limits on timing, size, and minimum prices for sales, may suspend sales at its discretion, and will pay the sales agents up to 3.0% of gross proceeds as commission.
United States Antimony Corp (UAMY) prospectus supplement highlights that the company remains in the exploration stage and lists a broad set of operational, regulatory, market, geopolitical and financing risks that could materially affect its business. The disclosure notes concentration risks, fluctuations in antimony and precious metal prices, potential environmental and security issues in Mexico, and cybersecurity and supply-chain concerns. The company also discloses potential stock dilution from outstanding equity awards and several warrant series exercisable at specified prices, and reserves shares under its Equity Incentive Plan.
United States Antimony Corp (UAMY) prospectus supplement highlights that the company remains in the exploration stage and lists a broad set of operational, regulatory, market, geopolitical and financing risks that could materially affect its business. The disclosure notes concentration risks, fluctuations in antimony and precious metal prices, potential environmental and security issues in Mexico, and cybersecurity and supply-chain concerns. The company also discloses potential stock dilution from outstanding equity awards and several warrant series exercisable at specified prices, and reserves shares under its Equity Incentive Plan.
United States Antimony Corp (UAMY) insider filing: Richard R. Isaak, SVP and Chief Financial Officer, reported awards on May 27, 2025 that were filed on Form 4. He received a time-based restricted stock unit award covering 180,000 common shares that vests one-third each on May 27 of 2025, 2026 and 2027, subject to continued service and shareholder approval of the company’s Amended Restated 2023 Equity Incentive Plan. He also received a stock option covering 200,000 underlying shares with an exercise price of $2.57, vesting upon satisfaction of specified performance measures during the option’s 10-year term and also conditioned on shareholder approval.
United States Antimony Corp (UAMY) insider filing: Richard R. Isaak, SVP and Chief Financial Officer, reported awards on May 27, 2025 that were filed on Form 4. He received a time-based restricted stock unit award covering 180,000 common shares that vests one-third each on May 27 of 2025, 2026 and 2027, subject to continued service and shareholder approval of the company’s Amended Restated 2023 Equity Incentive Plan. He also received a stock option covering 200,000 underlying shares with an exercise price of $2.57, vesting upon satisfaction of specified performance measures during the option’s 10-year term and also conditioned on shareholder approval.
John C. Gustavsen, President of the Antimony Division at United States Antimony Corp (UAMY), was granted equity awards on 05/27/2025 consisting of 125,000 restricted stock units (RSUs) and 150,000 stock options. Both grants are contingent on shareholder approval of the Issuer's Amended Restated 2023 Equity Incentive Plan.
The RSUs vest time-based in three equal installments (one-third or 41,667 shares on each of May 27, 2025, 2026 and 2027) subject to continued service and shareholder approval. The stock options vest upon achievement of specified performance measures at any time during the options' 10-year term, subject to continued service and shareholder approval. Following the reported transactions, the filings indicate 0 shares beneficially owned from these awards until vesting/approval conditions are met.
John C. Gustavsen, President of the Antimony Division at United States Antimony Corp (UAMY), was granted equity awards on 05/27/2025 consisting of 125,000 restricted stock units (RSUs) and 150,000 stock options. Both grants are contingent on shareholder approval of the Issuer's Amended Restated 2023 Equity Incentive Plan.
The RSUs vest time-based in three equal installments (one-third or 41,667 shares on each of May 27, 2025, 2026 and 2027) subject to continued service and shareholder approval. The stock options vest upon achievement of specified performance measures at any time during the options' 10-year term, subject to continued service and shareholder approval. Following the reported transactions, the filings indicate 0 shares beneficially owned from these awards until vesting/approval conditions are met.
Melissa M. Pagen, SVP of Corporate Development & Government Relations at United States Antimony Corp (UAMY), reported awards granted on 05/27/2025 that are contingent on shareholder approval of the companys Amended Restated 2023 Equity Incentive Plan. The filing shows a time-based RSU award for 100,000 shares vesting one-third on each of May 27, 2026, 2027 and 2028 subject to continued service and plan approval. It also shows a stock option for 150,000 shares with a $2.57 exercise price that vests upon meeting specified performance measures during its 10-year term, also contingent on shareholder approval. The Form 4 is signed 09/15/2025.
Melissa M. Pagen, SVP of Corporate Development & Government Relations at United States Antimony Corp (UAMY), reported awards granted on 05/27/2025 that are contingent on shareholder approval of the companys Amended Restated 2023 Equity Incentive Plan. The filing shows a time-based RSU award for 100,000 shares vesting one-third on each of May 27, 2026, 2027 and 2028 subject to continued service and plan approval. It also shows a stock option for 150,000 shares with a $2.57 exercise price that vests upon meeting specified performance measures during its 10-year term, also contingent on shareholder approval. The Form 4 is signed 09/15/2025.